Definitive radiation therapy with dose escalation is beneficial for patients with squamous cell cancer of the esophagus Ghosh-Laskar S, Mummudi N, Kumar S, Chandre M, Mishra S, Tibdewal A, Agarwal JP, Patil V, Noronha V, Prabash K, Patil P, Jiwnani S, Karimundackal G, Pramesh C S,

ORIGINAL ARTICLE

Ahead of Print

Definitive radiation therapy with dose escalation is beneficial for patients with squamous cell cancer of the esophagus Sarbani Ghosh-Laskar¹, Naveen Mummudi¹, Saurabha Kumar², Mukesh Chandre³, Shagun Mishra⁴, Anil Tibdewal¹, Jai Praklash Agarwal¹, Vijay Patil⁵, Vanita Noronha⁵, Kumar Prabash⁵, Prachi Patil⁶, Sabita Jiwnani⁷, George Karimundackal⁷, CS Pramesh⁷ ¹ Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India ² Department of Radiation Oncology, Mazumdar Shaw Cancer Center, Bengaluru, Karnataka, India ³ Department of Radiation Oncology, NAMCO Charitable Trust Hospital, Nashik, Maharashtra, India ⁴ Department of Radiation Oncology, Sanjay Gandhi Post Graduate Institute, Lucknow, Uttar Pradesh, India ⁵ Department of Medical Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India ⁶ Department of Gastrenterology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India ⁷ Department of Thoracic Surgery, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra, India Correspondence Address: Sarbani Ghosh-Laskar, Department of Radiation Oncology, Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, Maharashtra India Source of Support: None, Conflict of Interest: None DOI: 10.4103/jcrt.JCRT_404_20

Objective: We report the long term follow-up, toxicity, and outcomes of patients with localized squamous cell carcinoma of the esophagus(ESCC) who underwent definitive chemo-radiotherapy(dCRT) at our institute. Materials and Methods: Patients diagnosed with carcinoma post cricoid, upper cervical and thoracic oesophagus and treated with dCRT between January 2000 and March 2012 were retrospectively analyzed. Radiotherapy was delivered in two phases to a maximum dose of 63Gy in daily fractions of 1.8Gy using conventional or conformal techniques. OS and PFS were defined from date of registration and were calculated by Kaplan-Meier method with comparisons between different subgroups performed using log-rank test. All data were analysed using SPSS Version 22. Results: Three hundred and fourteen patients with ESCC treated with dCRT were included in this analysis. Median age at presentation was 56 years and median KPS at presentation was 70. Two-third of patients were treated with conformal technique. Median dose of radiation delivered was 60Gy(range 30.6Gy–70Gy). Neoadjuvant chemotherapy was administered in about 35% patients and 57% patients received concurrent chemotherapy. About 10% patients required hospitalization during treatment due to complications and 7 patients did not complete treatment. Grade 1/2 dermatitis and mucositis was seen in 77% and 71% patients respectively. Complete response at first follow up was observed in 56% of patients. At a median follow up of 56 months, 77 patients were alive with controlled disease. The 1- and 3-yr OS were 80% and 62% respectively. Median PFS was 28 months; 1- and 3-yr PFS were 66% and 46% respectively. A higher RT dose was found to be a significant predictor for OS and PFS on both uni- and multivariate analysis. Conclusion: Our study highlights that the delivery of higher RT doses (≥63Gy) is feasible in this patient group and that a higher RT dose was associated with significantly better PFS and OS.

  Search Pubmed for

    -  Ghosh-Laskar S
    -  Mummudi N
    -  Kumar S
    -  Chandre M
    -  Mishra S
    -  Tibdewal A
    -  Agarwal JP
    -  Patil V
    -  Noronha V
    -  Prabash K
    -  Patil P
    -  Jiwnani S
    -  Karimundackal G
    -  Pramesh C S

Citation Manager

Article Access Statistics

Reader Comments

* Requires registration (Free)

Article Access Statistics

Viewed	156

PDF Downloaded	2